Biogen (IDP) Stock Forecast & Price Target

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IDP Analyst Ratings

Moderate Buy

17 Buy

9 Hold

1 Sell

Based on 27 analysts giving stock ratings to

Biogen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IDP Stock 12 Month Forecast

Average Price Target

€203.53

▲(8.31% Upside)

Based on 27 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is €203.53 with a high forecast of €257.73 and a low forecast of €150.34. The average price target represents a 8.31% change from the last price of €187.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"113":"€113","258":"€258","149.25":"€149.3","185.5":"€185.5","221.75":"€221.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":257.729301,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€257.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":203.53144364478266,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€203.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150.34209225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€150.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[113,149.25,185.5,221.75,258],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.38,191.86840776923077,197.35681553846155,202.84522330769232,208.33363107692307,213.82203884615384,219.31044661538462,224.7988543846154,230.28726215384617,235.77566992307692,241.2640776923077,246.75248546153847,252.24089323076925,{"y":257.729301,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.38,187.69934181882942,189.01868363765885,190.3380254564883,191.65736727531774,192.97670909414717,194.2960509129766,195.61539273180605,196.93473455063548,198.2540763694649,199.57341818829434,200.8927600071238,202.21210182595323,{"y":203.53144364478266,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.38,183.60785325,180.8357065,178.06355975,175.291413,172.51926625,169.7471195,166.97497275,164.20282600000002,161.43067925,158.6585325,155.88638575,153.114239,{"y":150.34209225,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":114.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.45,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.46,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.42,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.38,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€257.73

Average Price Target€203.53

Lowest Price Target€150.34

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Morten Herholdt

HSBC

€141.75→€150.34

Sell

-20.00%

Downside

Reiterated

09/10/26

Biogen price target raised to $175 from $165 at HSBCBiogen price target raised to $175 from $165 at HSBC

Evan Seigerman

BMO Capital

―

Hold

―

Reiterated

09/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (NYSE: SYK), CVS Health (NYSE: CVS) and Biogen (NASDAQ: BIIB)

David Amsellem

Piper Sandler

€193.3→€210.48

Buy

12.00%

Upside

Reiterated

09/03/26

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), uniQure (QURE)

Brian Abrahams

RBC Capital

€206.18→€223.37

Buy

18.86%

Upside

Assigned

08/25/26

Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (NASDAQ: GEHC), Biogen (NASDAQ: BIIB) and BeOne Medicines (NASDAQ: ONC)

Alexandria Hammond

Wolfe Research

€257.73

Buy

37.15%

Upside

Upgraded

08/13/26

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE) and Biogen (NASDAQ: BIIB)

Emily Field

Barclays

€171.82

Hold

-8.57%

Downside

Reiterated

08/12/26

Barclays Keeps Their Hold Rating on Biogen (BIIB)

Geoff Meacham

Citi

€171.82→€184.71

Hold

-1.71%

Downside

Reiterated

08/03/26

Biogen price target raised to $215 from $200 at CitiBiogen price target raised to $215 from $200 at Citi

Salim Syed

Mizuho Securities

€189.86→€207.04

Buy

10.18%

Upside

Reiterated

08/03/26

Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)

Paul Matteis

Stifel Nicolaus

€183.85→€207.9

Buy

10.63%

Upside

Reiterated

08/02/26

Stifel Nicolaus Remains a Buy on Biogen (BIIB)

Laura Chico

Wedbush

€184.71

Hold

-1.71%

Downside

Reiterated

07/31/26

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

Danielle Brill

Truist Financial

€201.89

Buy

7.43%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Xencor (NASDAQ: XNCR)

Andrew Fein

H.C. Wainwright

€203.61→€215.63

Buy

14.75%

Upside

Reiterated

07/30/26

Biogen price target raised to $251 from $237 at H.C. WainwrightBiogen price target raised to $251 from $237 at H.C. Wainwright

Andrew Tsai

Jefferies

€219.07

Buy

16.58%

Upside

Reiterated

07/30/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), Teladoc (NYSE: TDOC) and Damora Therapeutics (NASDAQ: DMRA)

Mohit Bansal

Wells Fargo

€214.77

Buy

14.29%

Upside

Reiterated

07/30/26

Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)

Sumant Kulkarni

Canaccord Genuity

€210.48→€213.06

Buy

13.38%

Upside

Reiterated

07/30/26

Biogen price target raised to $248 from $245 at CanaccordBiogen price target raised to $248 from $245 at Canaccord

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Morten Herholdt

HSBC

€141.75→€150.34

Sell

-20.00%

Downside

Reiterated

09/10/26

Biogen price target raised to $175 from $165 at HSBCBiogen price target raised to $175 from $165 at HSBC

Evan Seigerman

BMO Capital

―

Hold

―

Reiterated

09/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (NYSE: SYK), CVS Health (NYSE: CVS) and Biogen (NASDAQ: BIIB)

David Amsellem

Piper Sandler

€193.3→€210.48

Buy

12.00%

Upside

Reiterated

09/03/26

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), uniQure (QURE)

Brian Abrahams

RBC Capital

€206.18→€223.37

Buy

18.86%

Upside

Assigned

08/25/26

Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (NASDAQ: GEHC), Biogen (NASDAQ: BIIB) and BeOne Medicines (NASDAQ: ONC)

Alexandria Hammond

Wolfe Research

€257.73

Buy

37.15%

Upside

Upgraded

08/13/26

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (NASDAQ: APGE) and Biogen (NASDAQ: BIIB)

Emily Field

Barclays

€171.82

Hold

-8.57%

Downside

Reiterated

08/12/26

Barclays Keeps Their Hold Rating on Biogen (BIIB)

Geoff Meacham

Citi

€171.82→€184.71

Hold

-1.71%

Downside

Reiterated

08/03/26

Biogen price target raised to $215 from $200 at CitiBiogen price target raised to $215 from $200 at Citi

Salim Syed

Mizuho Securities

€189.86→€207.04

Buy

10.18%

Upside

Reiterated

08/03/26

Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)

Paul Matteis

Stifel Nicolaus

€183.85→€207.9

Buy

10.63%

Upside

Reiterated

08/02/26

Stifel Nicolaus Remains a Buy on Biogen (BIIB)

Laura Chico

Wedbush

€184.71

Hold

-1.71%

Downside

Reiterated

07/31/26

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

Danielle Brill

Truist Financial

€201.89

Buy

7.43%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Xencor (NASDAQ: XNCR)

Andrew Fein

H.C. Wainwright

€203.61→€215.63

Buy

14.75%

Upside

Reiterated

07/30/26

Biogen price target raised to $251 from $237 at H.C. WainwrightBiogen price target raised to $251 from $237 at H.C. Wainwright

Andrew Tsai

Jefferies

€219.07

Buy

16.58%

Upside

Reiterated

07/30/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (NASDAQ: BIIB), Teladoc (NYSE: TDOC) and Damora Therapeutics (NASDAQ: DMRA)

Mohit Bansal

Wells Fargo

€214.77

Buy

14.29%

Upside

Reiterated

07/30/26

Wells Fargo Reaffirms Their Buy Rating on Biogen (BIIB)

Sumant Kulkarni

Canaccord Genuity

€210.48→€213.06

Buy

13.38%

Upside

Reiterated

07/30/26

Biogen price target raised to $248 from $245 at CanaccordBiogen price target raised to $248 from $245 at Canaccord

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

STOKStoke Therapeutics

AXGNAxoGen

JAZZJazz Pharmaceuticals

PTGXProtagonist Therapeutics

CABACabaletta Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months

Salveen RichterGoldman Sachs

Success Rate

16/27 ratings generated profit

Average Return

+1.76%

Copying Salveen Richter's trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +1.76% per trade.

1 Year

Myles MinterWilliam Blair

Success Rate

16/23 ratings generated profit

Average Return

+15.61%

Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +15.61% per trade.

2 Years

Myles MinterWilliam Blair

Success Rate

15/23 ratings generated profit

Average Return

+10.84%

Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +10.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDP Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IDP has received 34 Buy Ratings, 22 Hold Ratings, and 2 Sell Ratings. IDP average Analyst price target in the past 3 months is 203.53.

Each month's total comprises the sum of three months' worth of ratings.

IDP Financial Forecast

IDP Earnings Forecast

Next quarter’s earnings estimate for IDP is €1.75 with a range of €1.24 to €2.30. The previous quarter’s EPS was €3.11. IDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IDP has Performed in-line its overall industry.

IDP Sales Forecast

Next quarter’s sales forecast for IDP is €2.28B with a range of €2.16B to €2.35B. The previous quarter’s sales results were €2.26B. IDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IDP has Performed in-line its overall industry.

IDP Stock Forecast FAQ

What is DE:IDP’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is 203.53.

What is DE:IDP’s upside potential, based on the analysts’ average price target?

Biogen has 8.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Biogen a Buy, Sell or Hold?

Biogen has a consensus rating of Moderate Buy, which is based on 17 buy ratings, 9 hold ratings and 1 sell ratings.

What is Biogen’s share price target?

The average share price target for Biogen is 203.53. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €257.73 ,and the lowest forecast is €150.34. The average share price target represents 8.31% Increase from the current price of €187.92.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 27 Wall Streets Analysts.

How can I buy shares of Biogen?

To buy shares of DE:IDP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Biogen (IDP) Stock Forecast & Price Target

IDP Analyst Ratings

IDP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

IDP Analyst Recommendation Trends

IDP Financial Forecast

IDP Earnings Forecast

IDP Sales Forecast

IDP Stock Forecast FAQ

Detailed List of Analyst Forecasts